Johnson & Johnson (JNJ) has delivered a strong run for investors, with the stock up 0.7% over the past week, 5.9% over the last month, and an impressive 54.5% over the past 12 months. Looking ahead, Wall Street’s analysts are moderately bullish, with a 12‑month consensus price target of $236.08 versus a last closing price of $220.14, and an overall Analyst Consensus of “ModerateBuy.” This implies that, while the stock has already climbed significantly, analysts still see additional room for gains over the coming year.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
One of the key voices backing Johnson & Johnson is analyst Vamil Divan of Guggenheim Securities. On January 23, 2026, Divan reiterated a Buy rating on JNJ and set a price target of $240.00. That target sits slightly above the current consensus and signals further upside potential from current levels. His view aligns with the broader sentiment that the company remains well‑positioned despite its recent strong performance.
Divan’s latest report highlights Johnson & Johnson in the context of a broader healthcare and sector-wide update, noting JNJ under the “Revenue (B) — Price Target Change” section. While the fragment does not provide specific revenue projections or detailed commentary, the fact that the price target was affirmed at a premium to the market price reinforces confidence in the company’s fundamentals and earnings power. The reiteration suggests that, in his view, the recent rally does not fully capture JNJ’s long‑term value.
For investors, it is also worth noting Divan’s track record. He ranks 748 out of 11,984 experts, with a success rate of 56.3894523326572008% and an average return of 10.200% per rating. These metrics indicate that his calls have historically been more often right than wrong, and that his Buy rating on JNJ comes from an analyst with a solid performance history in stock selection.
Overall, Johnson & Johnson continues to trend positively in the eyes of Wall Street. The stock’s strong 12‑month rally, combined with a “ModerateBuy” consensus and a $236.08 average price target, paints a picture of a blue‑chip name that still has room to run, according to analysts. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.